Nurse Practitioner Program year 2025 Source: CMS Open Payments, 2026 publication

Amber Dreiling

Nurse Practitioner, Acute Care Topeka, KS Nurse Practitioner

NPI 1962018234 CMS profile 10846499

634 Sw Mulvane St, Topeka, KS 66606

Open in the dashboard

General payments

$486

24 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amber Dreiling of Topeka, KS is reported in the CMS Open Payments database as having received $486 across 24 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $486 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amber Dreiling
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Amber Dreiling were reported at $486. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Amber Dreiling Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $123 $38–$327 $132
2022 $0 $130 $44–$369 $149
2023 $0 $144 $49–$410 $160
2024 $0 $146 $48–$433 $164
2025 $486 $152 $48–$458 $169

Breakdown

Who paid General payments · program year 2025
  1. AbbVie, Inc. $101 4 payments
  2. Kerecis Limited $98 5 payments
  3. Smith+Nephew, Inc. $89 5 payments
  4. MIMEDX Group, Inc. $46 2 payments
  5. Organogenesis Inc. $33 2 payments
  6. Djo, LLC $28 1 payment
  7. Hydrofera LLC $19 1 payment
  8. Solventum Corporation $19 1 payment
  9. Viatris Specialty LLC $19 1 payment
  10. Reprise Biomedical, Inc. $17 1 payment
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $486 24 payments
Products named General payments · program year 2025
  1. DALVANCE $101 4 payments
  2. Kerecis SurgiClose Wound Care $98 5 payments
  3. Kerecis SurgiClose Wound Care $98 5 payments
  4. Kerecis SurgiClose Wound Care $98 5 payments
  5. Kerecis GraftGuide $98 5 payments
  6. Kerecis SurgiClose Wound Care $98 5 payments
  7. COLLAGENASE SANTYL $89 5 payments
  8. TEFLARO $76 3 payments
  9. DONJOY $28 1 payment
  10. HYDROFERA BLUE $19 1 payment
  11. Other $119 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record